 Kendra Conzen
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 18 | 2023 | 707 | 2.490 |
Why?
| | Obesity, Morbid | 4 | 2020 | 197 | 0.790 |
Why?
| | Living Donors | 9 | 2023 | 270 | 0.760 |
Why?
| | Venous Thrombosis | 2 | 2021 | 140 | 0.670 |
Why?
| | Liver Cirrhosis | 2 | 2020 | 227 | 0.660 |
Why?
| | Postoperative Complications | 4 | 2022 | 2128 | 0.610 |
Why?
| | Portal Vein | 2 | 2021 | 76 | 0.600 |
Why?
| | Transplant Recipients | 3 | 2023 | 140 | 0.510 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 63 | 0.480 |
Why?
| | Gastric Bypass | 3 | 2020 | 92 | 0.460 |
Why?
| | Tissue Donors | 2 | 2016 | 316 | 0.440 |
Why?
| | Cholestasis | 2 | 2016 | 225 | 0.420 |
Why?
| | Kidney Transplantation | 3 | 2023 | 541 | 0.370 |
Why?
| | Drainage | 1 | 2011 | 151 | 0.360 |
Why?
| | Decompression, Surgical | 1 | 2011 | 93 | 0.360 |
Why?
| | Catheterization | 1 | 2011 | 159 | 0.360 |
Why?
| | Reperfusion Injury | 4 | 2014 | 255 | 0.350 |
Why?
| | Liver | 9 | 2023 | 1637 | 0.340 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 225 | 0.340 |
Why?
| | Graft Survival | 6 | 2023 | 446 | 0.330 |
Why?
| | Donor Selection | 2 | 2020 | 66 | 0.290 |
Why?
| | Perioperative Care | 2 | 2017 | 127 | 0.240 |
Why?
| | Kidney Failure, Chronic | 2 | 2020 | 489 | 0.230 |
Why?
| | Graft Rejection | 2 | 2020 | 513 | 0.230 |
Why?
| | Fatty Liver | 3 | 2014 | 211 | 0.210 |
Why?
| | Thrombelastography | 2 | 2020 | 180 | 0.200 |
Why?
| | Treatment Outcome | 6 | 2022 | 9088 | 0.190 |
Why?
| | Reperfusion | 1 | 2020 | 36 | 0.180 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 40 | 0.170 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 78 | 0.170 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 1796 | 0.160 |
Why?
| | Blood Coagulation | 1 | 2020 | 218 | 0.160 |
Why?
| | Telomerase | 1 | 2020 | 206 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 197 | 0.150 |
Why?
| | Resuscitation | 1 | 2020 | 252 | 0.150 |
Why?
| | Retrospective Studies | 8 | 2023 | 12555 | 0.150 |
Why?
| | Transplantation, Homologous | 3 | 2020 | 377 | 0.150 |
Why?
| | Phlebography | 1 | 2017 | 34 | 0.150 |
Why?
| | Humans | 25 | 2023 | 114699 | 0.140 |
Why?
| | Bariatric Surgery | 1 | 2020 | 161 | 0.140 |
Why?
| | Anticoagulants | 2 | 2021 | 550 | 0.140 |
Why?
| | Incidental Findings | 1 | 2017 | 70 | 0.140 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 75 | 0.140 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 105 | 0.140 |
Why?
| | Allografts | 1 | 2017 | 122 | 0.140 |
Why?
| | Simulation Training | 1 | 2018 | 61 | 0.140 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 228 | 0.140 |
Why?
| | General Surgery | 1 | 2018 | 127 | 0.130 |
Why?
| | Surgeons | 1 | 2020 | 239 | 0.130 |
Why?
| | Waiting Lists | 1 | 2017 | 211 | 0.130 |
Why?
| | Parents | 2 | 2020 | 1186 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2017 | 2286 | 0.130 |
Why?
| | Airway Extubation | 1 | 2016 | 43 | 0.120 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 259 | 0.120 |
Why?
| | Male | 12 | 2021 | 55606 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2020 | 322 | 0.120 |
Why?
| | BH3 Interacting Domain Death Agonist Protein | 1 | 2014 | 10 | 0.120 |
Why?
| | Missouri | 2 | 2011 | 61 | 0.120 |
Why?
| | Gastrectomy | 3 | 2020 | 82 | 0.120 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 129 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 368 | 0.110 |
Why?
| | Hospitals, University | 1 | 2014 | 172 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 171 | 0.110 |
Why?
| | Reoperation | 2 | 2016 | 514 | 0.110 |
Why?
| | Adult | 9 | 2023 | 30553 | 0.110 |
Why?
| | Time Factors | 4 | 2020 | 6116 | 0.110 |
Why?
| | Registries | 1 | 2020 | 1768 | 0.100 |
Why?
| | Sex Factors | 1 | 2017 | 1715 | 0.100 |
Why?
| | Female | 9 | 2020 | 59520 | 0.100 |
Why?
| | Cholangiography | 1 | 2011 | 17 | 0.100 |
Why?
| | Prevalence | 1 | 2017 | 2251 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 893 | 0.090 |
Why?
| | Survival Analysis | 1 | 2014 | 1211 | 0.090 |
Why?
| | Molecular Chaperones | 1 | 2012 | 157 | 0.090 |
Why?
| | Radiographic Image Enhancement | 1 | 2011 | 52 | 0.090 |
Why?
| | Middle Aged | 7 | 2020 | 26738 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 608 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4411 | 0.090 |
Why?
| | Fibrinolysis | 2 | 2023 | 158 | 0.090 |
Why?
| | Mutation | 1 | 2020 | 3346 | 0.080 |
Why?
| | Hypoxia | 1 | 2016 | 958 | 0.080 |
Why?
| | Prospective Studies | 4 | 2022 | 6220 | 0.080 |
Why?
| | Liver Diseases | 1 | 2012 | 255 | 0.080 |
Why?
| | Endoplasmic Reticulum | 1 | 2011 | 234 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2014 | 1019 | 0.080 |
Why?
| | United States | 3 | 2020 | 12186 | 0.080 |
Why?
| | Hepatectomy | 2 | 2023 | 119 | 0.070 |
Why?
| | Stress, Physiological | 1 | 2011 | 378 | 0.070 |
Why?
| | Stents | 1 | 2011 | 475 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 1 | 2011 | 512 | 0.070 |
Why?
| | Heart Failure | 1 | 2020 | 1945 | 0.070 |
Why?
| | Body Mass Index | 1 | 2014 | 1959 | 0.070 |
Why?
| | Proteomics | 1 | 2012 | 836 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2012 | 3535 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 2968 | 0.060 |
Why?
| | Cohort Studies | 1 | 2014 | 4895 | 0.060 |
Why?
| | Hepatitis C Antibodies | 1 | 2004 | 9 | 0.060 |
Why?
| | Immunodominant Epitopes | 1 | 2004 | 25 | 0.060 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 25 | 0.050 |
Why?
| | Antibody Formation | 1 | 2004 | 266 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 68 | 0.050 |
Why?
| | Hepacivirus | 1 | 2004 | 229 | 0.050 |
Why?
| | Rats, Zucker | 2 | 2012 | 27 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 425 | 0.050 |
Why?
| | Child | 3 | 2021 | 18420 | 0.050 |
Why?
| | Dabigatran | 1 | 2021 | 22 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 51 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 45 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 81 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3053 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 103 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 140 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 476 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 150 | 0.040 |
Why?
| | Infant | 1 | 2011 | 7964 | 0.040 |
Why?
| | Child, Preschool | 1 | 2011 | 9118 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 136 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 4624 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 227 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 663 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1644 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 355 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 642 | 0.030 |
Why?
| | Prognosis | 1 | 2023 | 3329 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2014 | 37 | 0.030 |
Why?
| | Shock | 1 | 2016 | 84 | 0.030 |
Why?
| | Quality Improvement | 1 | 2022 | 950 | 0.030 |
Why?
| | Erythrocyte Transfusion | 1 | 2016 | 189 | 0.030 |
Why?
| | Cause of Death | 1 | 2016 | 361 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2313 | 0.030 |
Why?
| | Hemoglobins | 1 | 2016 | 315 | 0.030 |
Why?
| | Rats | 2 | 2012 | 4958 | 0.030 |
Why?
| | Warm Ischemia | 1 | 2012 | 11 | 0.030 |
Why?
| | Aged | 2 | 2021 | 19074 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 100 | 0.030 |
Why?
| | Databases, Protein | 1 | 2012 | 59 | 0.030 |
Why?
| | Transaminases | 1 | 2012 | 24 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2012 | 66 | 0.020 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 91 | 0.020 |
Why?
| | Animals | 4 | 2014 | 31708 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 235 | 0.020 |
Why?
| | Taurochenodeoxycholic Acid | 1 | 2011 | 7 | 0.020 |
Why?
| | Activating Transcription Factor 4 | 1 | 2011 | 18 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2011 | 28 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2012 | 470 | 0.020 |
Why?
| | Organ Size | 1 | 2011 | 436 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2011 | 113 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 594 | 0.020 |
Why?
| | Caspases | 1 | 2011 | 245 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 808 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 633 | 0.020 |
Why?
| | Proteome | 1 | 2012 | 339 | 0.020 |
Why?
| | Internship and Residency | 1 | 2018 | 926 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 370 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2570 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 477 | 0.020 |
Why?
| | Obesity | 1 | 2020 | 2508 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2011 | 245 | 0.020 |
Why?
| | Software | 1 | 2011 | 530 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 676 | 0.020 |
Why?
| | NF-kappa B | 1 | 2011 | 641 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3408 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 1841 | 0.010 |
Why?
| | Viral Core Proteins | 1 | 2004 | 20 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2765 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 4694 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 8632 | 0.010 |
Why?
| | Viral Load | 1 | 2004 | 405 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 797 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 10471 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1760 | 0.010 |
Why?
| | Peptides | 1 | 2004 | 848 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 4515 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 17853 | 0.010 |
Why?
| | Mice | 1 | 2012 | 14871 | 0.010 |
Why?
|
|
Conzen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|